B
Bone Biologics Corp
BBLGCIK 0001419554NasdaqNon-AcceleratedSmaller ReportingOrthopedic, Prosthetic & Surgical Appliances & SuppliesDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-3.11M
Total Assets
$5.80M
Equity
$5.38M
Shares Out
1.80M
Op. Cash Flow
$-2.70M
Business
Bone Biologics is a clinical-stage medical device company developing bone regeneration therapeutics using recombinant human NELL-1 protein combined with demineralized bone matrix (DBM). The lead product candidate, NB1, is designed for use in lumbar spinal fusion procedures and targets the orthopedic and spine surgery markets. The company has exclusive worldwide rights to NELL-1 technology from UCLA, is currently conducting a first-in-human pilot clinical study in Australia, and is advancing toward FDA pre-market approval pathway in the United States.
Summary from 10-K filed 2026-03-02
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | — | — | — | — | — | |
| Research and development | 1 | 2 | 7 | 2 | 82,044 | |
| General and administrative | 2 | 2 | 3 | 2 | 1 | |
| Total operating expenses | 3 | 4 | 9 | 4 | 1 | |
| Loss from operations | −3 | −4 | −9 | −4 | −1 | |
| Change in fair value of warrant liability | 3,967 | 51,081 | 892,693 | 3 | — | |
| Interest income | 121,984 | 55,660 | 1,868 | — | — | |
| Total other income | 125,951 | 106,741 | 479,572 | 2 | −507,609 | |
| Net loss | −3 | −4 | −9 | −1 | −2 | |
| Deemed dividend on warrant inducements | — | −3 | — | — | — | |
| Net loss attributable to common stockholders | −3 | −7 | −9 | — | — | |
| Weighted average shares outstanding - basic | 1 | 252,960 | 263,137 | 47,658 | — | |
| Weighted average shares outstanding - diluted | 1 | 252,960 | 263,137 | 47,658 | — | |
| Loss per share - basic | −2.65 | −28.96 | −34.01 | −31.15 | −0.35 | |
| Loss per share - diluted | −2.65 | −28.96 | −34.01 | −31.15 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 5 | 3 | 3 | 8 | 7 | |
| Advances on research and development contract services | 208,972 | 258,059 | 328,844 | 579,910 | — | |
| Prepaid insurance | 232,946 | 268,179 | 372,350 | 364,536 | — | |
| Interest Receivable | 9,895 | — | — | — | — | |
| Prepaid expenses | 10,000 | 10,000 | 10,000 | 12,479 | — | |
| Total current assets | 6 | 4 | 4 | 8 | — | |
| Total assets | 6 | 4 | 4 | 8 | 7 | |
| Accounts payable and accrued expenses | 417,884 | 373,042 | 360,662 | 104,786 | 99,909 | |
| Warrant liability | 703 | 4,670 | — | — | — | |
| Total current liabilities | 418,587 | 377,712 | 831,402 | 3 | 99,909 | |
| Total liabilities | 418,587 | 377,712 | 831,402 | 3 | 99,909 | |
| Commitments and Contingencies | — | — | — | — | — | |
| Preferred Stock, $0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at December 31, 2025 and 2024 | — | — | — | — | — | |
| Common stock, $0.001 par value per share; 100,000,000 shares authorized; 1,795,260 and 492,417 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1,795 | 492 | 534 | 64 | 10,350 | |
| Additional paid-in capital | 94 | 89 | 84 | 78 | 77 | |
| Accumulated deficit | −88 | −85 | −81 | −72 | −70 | |
| Total stockholders equity | 5 | 3 | 3 | 6 | 7 | |
| Total liabilities and stockholders equity | 6 | 4 | 4 | 8 | 7 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 256,358 | 188,819 | 152,599 | 266,633 | 207,035 | |
| Advances on research and development contract services | 49,087 | 70,785 | 251,066 | −579,910 | — | |
| Prepaid insurance | 35,233 | 104,171 | — | — | — | |
| Interest receivable | −9,895 | — | — | — | — | |
| Accounts payable and accrued expenses | 91,025 | 89,780 | 255,876 | 4,877 | −365,487 | |
| Accrued legal settlement | — | −414,989 | 414,989 | — | — | |
| Net cash used in operating activities | −3 | −4 | −10 | −4 | −1 | |
| Proceeds from issuance of common shares from ATM, net of costs | 347,549 | 1 | — | — | — | |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | 4 | 2 | 5 | 4 | 7 | |
| Proceeds from issuance of common shares from warrant inducement, net of costs | — | 2 | — | — | — | |
| Exercise of pre-funded warrants | — | 662 | — | — | — | |
| Net cash provided by financing activities | 5 | 4 | 5 | 4 | 8 | |
| Net increase in cash | 2 | 298,562 | −5 | 862,947 | 7 | |
| Income taxes paid | — | — | — | — | — | |
| Options issued to settle accrued bonus | 46,183 | 77,400 | — | — | — | |
| Deemed dividend warrant inducement | — | 3 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Bone Biologics Corp's CIK number?
Bone Biologics Corp's SEC CIK number is 0001419554 (1419554). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Bone Biologics Corp's SEC filings?
All of Bone Biologics Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.